Can-Fite BioPharma Ltd. CANF
Set alert
1.62 USD -0.04 -2.41%
At close · Oct 30
1.69 +0.07 +4.17%
After hours · Oct 30, 4:00 PM ET
1.60 Day range 1.70
1.62 52-week range 8.60
- YTD
- -59.50%
- 1 year
- -81.16%
- Open
- 1.68
- Prev close
- 1.66
- Mkt cap
- 4.91M
- Vol
- 22.44K
- Avg vol
- 376.27K
- EPS
- -13.23
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.60
- High
- 1.70
- Forward P/E
- -2.00
- Beta
- 0.57
- Short ratio
- 1.96
- Inst. own
- 8.02%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.08
- 200-d avg
- 2.37
- 1y target
- 14.00
2Y chart
Events in this range
- Nov 12, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Dec 5, 2024Rating: D. Boral Capital · Buy → Buy
- Jan 5, 2026Split: 1 for 20
Signals (74)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 28, 2026 | 3 days ago |
| RSI: Oversold | Oct 23, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 19, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 16, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 8, 2026 | 3 weeks ago |
| MACD: Buy Signal | Sep 24, 2026 | 1 month ago |
| RSI: Oversold | Sep 23, 2026 | 1 month ago |
| RSI: Oversold | Sep 2, 2026 | 1 month ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 24, 2026 | 2 months ago |
| SMA: Bullish | Aug 6, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 6, 2026 | 2 months ago |
| SMA: Bearish | Jul 31, 2026 | 3 months ago |
| SMA: Bullish | Jul 30, 2026 | 3 months ago |
| SMA: Bearish | Jul 23, 2026 | 3 months ago |
| SMA: Bullish | Jul 15, 2026 | 3 months ago |
| SMA: Bearish | Jul 14, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 14, 2026 | 3 months ago |
| SMA: Bullish | Jul 1, 2026 | 4 months ago |
| RSI: Overbought | Jul 1, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 30, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 26, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 22, 2026 | 4 months ago |
| SMA: Bearish | Jun 2, 2026 | 5 months ago |
| MACD: Sell Signal | May 28, 2026 | 5 months ago |
| SMA: Bullish | May 12, 2026 | 5 months ago |
| SMA: Bearish | May 11, 2026 | 5 months ago |
| SMA: Bullish | May 7, 2026 | 5 months ago |
| MACD: Buy Signal | Apr 7, 2026 | 6 months ago |
| SMA: Bearish | Mar 9, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 9, 2026 | 7 months ago |
| RSI: Overbought | Mar 4, 2026 | 8 months ago |
| SMA: Bullish | Feb 25, 2026 | 8 months ago |
| SMA: Bearish | Feb 24, 2026 | 8 months ago |
| SMA: Bullish | Feb 20, 2026 | 8 months ago |
| MACD: Buy Signal | Jan 5, 2026 | 9 months ago |
| RSI: Oversold | Dec 29, 2025 | 10 months ago |
| RSI: Oversold | Dec 22, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 15, 2025 | 10 months ago |
| MACD: Buy Signal | Nov 26, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 19, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 18, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 14, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 10, 2025 | 11 months ago |
| RSI: Oversold | Oct 23, 2025 | 1 year ago |
| RSI: Oversold | Oct 17, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 9, 2025 | 1 year ago |
| RSI: Oversold | Oct 8, 2025 | 1 year ago |
| RSI: Oversold | Sep 24, 2025 | 1 year ago |
| RSI: Oversold | Aug 29, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 14, 2025 | 1 year ago |
| RSI: Oversold | Jul 28, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 25, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 10, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 26, 2025 | 1 year ago |
| MACD: Buy Signal | May 6, 2025 | 1 year ago |
| SMA: Bearish | Apr 14, 2025 | 1 year ago |
| SMA: Bullish | Apr 11, 2025 | 1 year ago |
| SMA: Bearish | Mar 25, 2025 | 1 year ago |
| SMA: Bullish | Mar 21, 2025 | 1 year ago |
| SMA: Bearish | Mar 20, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 20, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 18, 2025 | 1 year ago |
| RSI: Overbought | Mar 18, 2025 | 1 year ago |
| SMA: Bullish | Mar 14, 2025 | 1 year ago |
| SMA: Bearish | Mar 7, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 6, 2025 | 1 year ago |
| RSI: Overbought | Feb 20, 2025 | 1 year ago |
| SMA: Bullish | Feb 18, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 12, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 3, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 27, 2024 | 1 year ago |
| RSI: Oversold | Dec 16, 2024 | 1 year ago |
| RSI: Oversold | Dec 4, 2024 | 1 year ago |
Key statistics
- Market cap
- 8.90M
- Enterprise value
- 2.47B
- Trailing P/E
- 0.00
- Forward P/E
- -2.00
- PEG ratio
- 0.00
- Price / sales
- 13.34
- Price / book
- 1460.00
- EPS (TTM)
- -2.60
- Beta
- 0.57
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 667.00K
- Revenue growth
- -19.40%
- Free cash flow
- -4.55M
- Total cash
- 4.73M
- Total debt
- 57.00K
- Return on equity
- -157.62%
- Shares outstanding
- 6.10M
- Short % of float
- 2.51%
- 50-day average
- 2.08
- 200-day average
- 2.37
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 14.00 +764.2% upside
Now 1.62
- Target (low)
- 10.00
- Target (mean)
- 14.00
- Target (high)
- 18.00
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
CANF Revenue — quarterly 204.00K
CANF Net income — quarterly -4.12M
CANF EPS — quarterly -60.00
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 5, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 17, 2024 | EF Hutton | init | — | Buy |
| May 9, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 24, 2023 | HC Wainwright & Co. | main | Buy | Buy |
| Jun 2, 2023 | HC Wainwright & Co. | reit | — | Buy |
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- canfite.com
News
- Can-Fite Presents Phase IIa Namodenoson Data In Advanced Pancreatic Cancer, Meeting Primary Safety Endpoint And Showing Encouraging Survival Outcomes
- Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026
- Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation
- Can Fite Biofarma H1 EPS $(1.24) Beats $(1.43) Estimate, Sales $202.000K, Same YoY
- Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study
- Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study
- Can-Fite BioPharma To Receive ~$4M From Exercise Of 1,591,738 Warrants At Reduced $2.50/ADS Price
- Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
Your note
Sign in to keep a note on CANF — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 42.17% | 650,000 | 949.00K | Sep 29, 2024 |
| Morgan Stanley | 3.29% | 50,660 | 73.96K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 1.92% | 29,570 | 43.17K | Sep 29, 2024 |
| Rhumbline Advisers | 1.10% | 16,945 | 24.74K | Sep 29, 2024 |
| Fifth Third Bancorp | 0.19% | 3,000 | 4.38K | Sep 29, 2024 |
| Wells Fargo & Company | 0.16% | 2,500 | 3.65K | Sep 29, 2024 |